Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HEBE, A novel chimeric chronokine for ameliorating memory deficits in Alzheimer's disease

  • Esandi Jauregui, Jon|||0000-0001-5529-2686
  • Renault de Barros, Pedro Victor|||0000-0002-5649-3057
  • Capilla López, Maria Dolores|||0000-0002-9483-4887
  • Blanch Garcia, Rebeca|||0000-0001-6726-4084
  • Edo Salvador, Ángel
  • Ramirez-Gómez, David
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Almolda Ardid, Beatriz|||0000-0001-6631-4385
  • Saura, Carlos Alberto
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-β and Tau protein depositions, with treatments focusing on single proteins have shown limited success due to the complexity of pathways involved. This study explored the potential of chronokines -proteins that modulate aging-related processes- as an alternative therapeutic approach. Specifically, we focused on a novel pleiotropic chimeric protein named HEBE, combining s-KL, sTREM2 and TIMP2, guided by bioinformatic analyses to ensure the preservation of each protein's conformation, crucial for their functions. In vitro studies confirmed HEBE's stability and enzymatic activities, even suggesting it has different activities compared to the individual chronokines. In vivo experiments on APP/Tau mice revealed improved learning and memory functions with HEBE treatment, along with decreased levels of phosphorylated Tau and minor effects on amyloid-β levels. These findings suggest that HEBE is as a promising therapeutic candidate for ameliorating memory deficits and reducing pTau in an AD mouse model.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gene therapy rescues brain edema and motor function in a mouse model of megalencephalic leukoencephalopathy with subcortical cysts

  • Brao, Alejandro
  • Sánchez Osuna, Ángela
  • Rodríguez Reverté, Irina
  • Prat, Esther
  • DEL REY AZPIRI, JAVIER
  • Lope-Piedrafita, Silvia
  • Chillon, Miguel
  • Bosch, Assumpció
Gene therapy; Megalencephalic leukoencephalopathy with subcortical cysts; White matter, Teràpia gènica; Leucoencefalopatia megalencefàlica amb quists subcorticals; Matèria blanca, Terapia génica; Leucoencefalopatía megalencefálica con quistes subcorticales; Materia blanca, Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is an ultrarare, infantile-onset leukodystrophy characterized by white matter edema for which there is no treatment. More than 75% of diagnosed cases result from biallelic loss-of-function mutations in the astrocyte-specific gene MLC1, leading to early-onset macrocephaly, cerebellar ataxia, epilepsy, and mild cognitive decline. To develop a gene therapy for MLC, we administered an adeno-associated viral vector capable of crossing the murine blood-brain barrier, delivering the human MLC1 cDNA under the control of a human astrocyte-specific promoter, to 10-month-old Mlc1−/− mice. We observed long-term astrocyte-driven expression of MLC1 up to 1 year after viral vector administration in all brain areas analyzed. Despite the late-stage intervention, in vivo magnetic resonance imaging revealed normalization of water accumulation. Notably, our therapy successfully reversed locomotor deficits in Mlc1−/− mice, as evidenced by improved performance in motor tests assessing cerebellar ataxia-like behaviors. Collectively, these findings not only demonstrate the sustained efficacy of our gene therapy but also highlight the reversibility of vacuolation and motor impairments in Mlc1−/− mice, suggesting that MLC patients could benefit from treatment even after symptom onset., This study was funded by the European Leukodystrophies Association (ELA2018-005I2, ELA2022-004I2 to A.Bosch), the Spanish Network of Advanced Therapies (TERAV), NextGenerationEU – Recovery, Transformation and Resilience Plan (RD21/0017/0008 to M.C.), Generalitat de Catalunya (2021-SGR00529 to A.Bosch, 2024 FI-1 0080 to I.R.), the Spanish Ministry of Universities (FPU20/00187 to A.Brao), and the Spanish Ministry of Science and Innovation (PID2021-126246NB-I00 to R.E.). We thank Jorge Lunar (Institute of Neurosciences, Universitat Autònoma de Barcelona) for his valuable technical assistance. This article is dedicated to the memory of Virginia Nunes.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

  • Buñuales, María
  • Garduno, Angeles
  • Chillon, Miguel
  • GONZALEZ-APARICIO, MANUELA
  • Espelosin, Maria
  • Bosch, Assumpció
Characterization of brain; Adeno-associated viral vectors; Expression profiles, Transducció cerebral; Vectores virales adenoasociados; Perfils d'expressió, Transducción cerebral; Vectores virales adenoasociados; Perfiles de expresión, Different screening methods are being developed to generate adeno-associated viral vectors (AAV) with the ability to bypass the blood-brain barrier (BBB) upon intravenous administration. Recently, the AAV9P31 stood out as the most efficient version among a library of peptide-displaying capsids selected in C57BL/6 mice using RNA-driven biopanning. In this work we have characterized in detail its biodistribution in different mouse strains (C57BL/6 and Balb/c), as well as in Sprague Dawley rats and non-human primates (Macaca fascicularis). Using GFP and NanoLuc reporter genes, we confirmed homogeneous infection and transgene expression across the CNS of mice injected intravenously with AAV9P31. A more restricted pattern was observed upon either intracerebroventricular or intraparenchymal injection. Following intravenous delivery, region- and cell-specific differential patterns of transduction were observed in the mouse brain, including a preferential transduction of astrocytes and neurons in the cerebral cortex and striatum, whereas neurons were the only transduced cell type in subcortical locations across the hippocampus, thalamus, hypothalamus, mesencephalon, brainstem and cerebellum. Furthermore, transduced microglial cells were never found in any CNS location. Peripheral organs transduced upon intravenous administration included lung, liver, peritoneum, heart and skeletal muscle. However, a comparable performance of AAV9P31 to bypass the BBB in rats and macaques was not observed, although a more limited neuronal transduction was found in the brainstem of rats upon intravenous delivery. Finally, intracerebroventricular delivery in macaques resulted in neuronal transduction in cortical, subcortical structures and cerebellum following a patchy pattern. In conclusion, the widespread CNS transduction obtained in mice upon intravenous delivery of AAV9P31 represents a powerful tool for modeling a wide variety of neurological disorders as well as an appealing choice for the evaluation of gene therapy-based therapeutics., The authors declare that financial support was received for the research, authorship, and/or publication of this article. Conducted work was funded by MCIN/AEI/10.13039/501100011033/ PID2019-104034RB-I00, PID2020-120308RB, PID2021-128587OB-I00 FEDER, UE, TERAV/ISCIII Next Generation EU-PRTR RD21/0017/0034 and RD21/0017/0008, Generalitat de Catalunya 2021-SGR 00529, Apoyo Dravet Foundation and Desafia Dravet Association. MGA is supported in part by a Pedro Lopez Berastegui grant. AG was supported by CONAHCYT fellowship, Mexico (936633).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells, Proof of Concept and Regulatory Compliance

  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Hernández Martín, Joaquim|||0000-0003-1409-5568
  • Mirabel, Clémentine
  • Puigdomenech-poch, Maria
  • Romeo-Guitart, David|||0000-0003-3368-9302
  • Marmolejo Martínez-Artesero, Sara|||0000-0001-5357-2123
  • Cabrera-Pérez, Raquel|||0000-0002-4858-0142
  • Jaramillo, Jessica
  • Kumru, Hatice|||0000-0002-0501-1660
  • García López, Joan
  • Vidal-Samsó, Joan
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
(1) Background: the use of Mesenchymal Stromal Cells (MSC) in emerging therapies for spinal cord injury (SCI) hold the potential to improve functional recovery. However, the development of cell-based medicines is challenging and preclinical studies addressing quality, safety and efficacy must be conducted prior to clinical testing; (2) Methods: herein we present (i) the characterization of the quality attributes of MSC from the Wharton's jelly (WJ) of the umbilical cord, (ii) safety of intrathecal infusion in a 3-month subchronic toxicity assessment study, and (iii) efficacy in a rat SCI model by controlled impaction (100 kdynes) after single (day 7 post-injury) and repeated dose of 1 × 10 MSC,WJ (days 7 and 14 post-injury) with 70-day monitoring by electrophysiological testing, motor function assessment and histology evaluation; (3) Results: no toxicity associated to MSC,WJ infusion was observed. Regarding efficacy, recovery of locomotion was promoted at early time points. Persistence of MSC,WJ was detected early after administration (day 2 post-injection) but not at days 14 and 63 post-injection. (4) Conclusions: the safety profile and signs of efficacy substantiate the suitability of the presented data for inclusion in the Investigational Medicinal Product Dossier for further consideration by the competent Regulatory Authority to proceed with clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel decellularized nerve graft for repairing peripheral nerve long gap injury in the rat

  • Contreras, Estefanía|||0000-0002-8645-2790
  • Bolívar Martín, Sara|||0000-0003-2966-6845
  • Nieto-Nicolau, Núria|||0000-0002-3527-0110
  • Fariñas Barbera, Oscar|||0000-0003-1188-4529
  • López Chicón, Patricia
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Udina i Bonet, Esther|||0000-0003-1954-8562
Decellularized nerve allografts are an alternative to autograft for repairing severe nerve injuries, since they have higher availability and do not induce rejection. In this study, we have assessed the regenerative potential of a novel decellularization protocol for human and rat nerves for repairing nerve resections, compared to the gold standard autograft. A 15-mm gap in the sciatic nerve was repaired with decellularized rat allograft (DC-RA), decellularized human xenograft (DC-HX), or fresh autograft (AG). Electrophysiology tests were performed monthly to evaluate muscle reinnervation, whereas histological and immunohistochemical analyses of the grafts were evaluated at 4 months. A short-term study was also performed to compare the differences between the two decellularized grafts (DC-RA and DC-HX) in early phases of regeneration. The decellularization process eliminated cellularity while preserving the ECM and endoneurial tubules of both rat and human nerves. Higher amount of reinnervation was observed in the AG group compared to the DC-RA group, while only half of the animals of the DC-HX showed distal muscle reinnervation. The number of regenerating myelinated axons in the mid-graft was similar between AG and DC-RA and lower in DC-HX graft, but significantly lower in both DC grafts distally. At short term, fibroblasts repopulated the DC-RA graft, supporting regenerated axons, whereas an important fibrotic reaction was observed around DC-HX grafts. In conclusion, the decellularized allograft sustained regeneration through a long gap in the rat although at a slower rate compared to the ideal autograft, whereas regeneration was limited or even failed when using a decellularized xenograft.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sensory Involvement in Amyotrophic Lateral Sclerosis

  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Herrando-Grabulosa, Mireia|||0000-0002-6685-3220
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Although amyotrophic lateral sclerosis (ALS) is pre-eminently a motor disease, the existence of non-motor manifestations, including sensory involvement, has been described in the last few years. Although from a clinical perspective, sensory symptoms are overshadowed by their motor manifestations, this does not mean that their pathological significance is not relevant. In this review, we have made an extensive description of the involvement of sensory and autonomic systems described to date in ALS, from clinical, neurophysiological, neuroimaging, neuropathological, functional, and molecular perspectives.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Gene therapy rescues brain edema and motor function in a mouse model of megalencephalic leukoencephalopathy with subcortical cysts

  • Brao, Alejandro
  • Sánchez Osuna, Ángela
  • Rodríguez Reverté, Irina
  • Prat, Esther
  • DEL REY AZPIRI, JAVIER
  • Lope-Piedrafita, Silvia
  • Chillon, Miguel
  • Bosch, Assumpció
Gene therapy; Megalencephalic leukoencephalopathy with subcortical cysts; White matter, Teràpia gènica; Leucoencefalopatia megalencefàlica amb quists subcorticals; Matèria blanca, Terapia génica; Leucoencefalopatía megalencefálica con quistes subcorticales; Materia blanca, Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is an ultrarare, infantile-onset leukodystrophy characterized by white matter edema for which there is no treatment. More than 75% of diagnosed cases result from biallelic loss-of-function mutations in the astrocyte-specific gene MLC1, leading to early-onset macrocephaly, cerebellar ataxia, epilepsy, and mild cognitive decline. To develop a gene therapy for MLC, we administered an adeno-associated viral vector capable of crossing the murine blood-brain barrier, delivering the human MLC1 cDNA under the control of a human astrocyte-specific promoter, to 10-month-old Mlc1−/− mice. We observed long-term astrocyte-driven expression of MLC1 up to 1 year after viral vector administration in all brain areas analyzed. Despite the late-stage intervention, in vivo magnetic resonance imaging revealed normalization of water accumulation. Notably, our therapy successfully reversed locomotor deficits in Mlc1−/− mice, as evidenced by improved performance in motor tests assessing cerebellar ataxia-like behaviors. Collectively, these findings not only demonstrate the sustained efficacy of our gene therapy but also highlight the reversibility of vacuolation and motor impairments in Mlc1−/− mice, suggesting that MLC patients could benefit from treatment even after symptom onset., This study was funded by the European Leukodystrophies Association (ELA2018-005I2, ELA2022-004I2 to A.Bosch), the Spanish Network of Advanced Therapies (TERAV), NextGenerationEU – Recovery, Transformation and Resilience Plan (RD21/0017/0008 to M.C.), Generalitat de Catalunya (2021-SGR00529 to A.Bosch, 2024 FI-1 0080 to I.R.), the Spanish Ministry of Universities (FPU20/00187 to A.Brao), and the Spanish Ministry of Science and Innovation (PID2021-126246NB-I00 to R.E.). We thank Jorge Lunar (Institute of Neurosciences, Universitat Autònoma de Barcelona) for his valuable technical assistance. This article is dedicated to the memory of Virginia Nunes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

  • Buñuales, María
  • Garduno, Angeles
  • Chillon, Miguel
  • GONZALEZ-APARICIO, MANUELA
  • Espelosin, Maria
  • Bosch, Assumpció
Characterization of brain; Adeno-associated viral vectors; Expression profiles, Transducció cerebral; Vectores virales adenoasociados; Perfils d'expressió, Transducción cerebral; Vectores virales adenoasociados; Perfiles de expresión, Different screening methods are being developed to generate adeno-associated viral vectors (AAV) with the ability to bypass the blood-brain barrier (BBB) upon intravenous administration. Recently, the AAV9P31 stood out as the most efficient version among a library of peptide-displaying capsids selected in C57BL/6 mice using RNA-driven biopanning. In this work we have characterized in detail its biodistribution in different mouse strains (C57BL/6 and Balb/c), as well as in Sprague Dawley rats and non-human primates (Macaca fascicularis). Using GFP and NanoLuc reporter genes, we confirmed homogeneous infection and transgene expression across the CNS of mice injected intravenously with AAV9P31. A more restricted pattern was observed upon either intracerebroventricular or intraparenchymal injection. Following intravenous delivery, region- and cell-specific differential patterns of transduction were observed in the mouse brain, including a preferential transduction of astrocytes and neurons in the cerebral cortex and striatum, whereas neurons were the only transduced cell type in subcortical locations across the hippocampus, thalamus, hypothalamus, mesencephalon, brainstem and cerebellum. Furthermore, transduced microglial cells were never found in any CNS location. Peripheral organs transduced upon intravenous administration included lung, liver, peritoneum, heart and skeletal muscle. However, a comparable performance of AAV9P31 to bypass the BBB in rats and macaques was not observed, although a more limited neuronal transduction was found in the brainstem of rats upon intravenous delivery. Finally, intracerebroventricular delivery in macaques resulted in neuronal transduction in cortical, subcortical structures and cerebellum following a patchy pattern. In conclusion, the widespread CNS transduction obtained in mice upon intravenous delivery of AAV9P31 represents a powerful tool for modeling a wide variety of neurological disorders as well as an appealing choice for the evaluation of gene therapy-based therapeutics., The authors declare that financial support was received for the research, authorship, and/or publication of this article. Conducted work was funded by MCIN/AEI/10.13039/501100011033/ PID2019-104034RB-I00, PID2020-120308RB, PID2021-128587OB-I00 FEDER, UE, TERAV/ISCIII Next Generation EU-PRTR RD21/0017/0034 and RD21/0017/0008, Generalitat de Catalunya 2021-SGR 00529, Apoyo Dravet Foundation and Desafia Dravet Association. MGA is supported in part by a Pedro Lopez Berastegui grant. AG was supported by CONAHCYT fellowship, Mexico (936633).